Work

CAR‐T cells in first relapse of paediatric Down syndrome B‐cell acute lymphoblastic leukaemia: Oncologist perspectives

Year: 2026
Type: article
Study design: Observational Study
Abstract: Management of B-cell acute lymphoblastic leukaemia (B-ALL) in patients with Down syndrome (DS-ALL) is complicated by increased toxicity and relapse rates. For first relapse of DS-ALL, optimal management is uncertain. Chimeric antigen receptor T-cell (CAR-T) therapy offers an alternate approach for remission induction and/or definitive curative therapy, and recent reports suggest similar efficacy and tolerability in DS and non-DS patients. We distributed an international survey to paediatric oncologists treating DS-ALL querying opinions on therapy, monitoring and toxicity in this population. Among 89 respondents, 76%, 80% and 64% favoured definitive CAR-T therapy without intent for subsequent haematopoietic stem cell transplantation (HSCT) for early medullary relapse, early and late isolated extra-medullary relapse respectively. For late medullary relapse, 47% preferred definitive CAR-T whereas 51% chose definitive chemoimmunotherapy. Only a minority of respondents selected HSCT as a planned approach for any first relapse: 11%-15% for early relapse; 3%-5% for late relapse. The main perceived benefit of CAR-T therapy was its favourable toxicity profile. Overall, 56% and 77% of respondents felt that it should be considered standard of care for low and high-risk relapse of DS-ALL respectively. Survey responses suggest that developing guidelines to integrate use of CAR-T is warranted for first relapse in DS-ALL.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W7236635551
FWCI:
Cites: 24
Cited by:
Related to: 10